Stocks · Healthcare · Biotechnology
Veradermics, Incorporated MANE
$116.76 -0.39% Close, Oct 2, 2026 · NYSE · Market cap $4.88B
Next earnings report: Nov 10, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count fell 79.9% in a year, mainly through buybacks.
- The company holds net cash of $318.9M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 44%
- Accruals (lower is better)Bottom 22%
- Interest coverBottom 10%
How cheap the shares are relative to earnings, cash flow and their own history.
- Free-cash-flow yieldTop 41%
- EBITDA / enterprise valueTop 43%
Strength and persistence of the price trend, including versus the S&P 500.
- 6-month returnTop 12%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 16%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 40%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 34%
- Maximum drawdown, 3 yearsTop 2%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -12.6% | — | Top 44% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -1.7%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -193.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -5.52%
- Shareholder yield
- -5.52%
- Share count change, 1 year
- -79.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 2 of 3
- Average EPS surprise, last 4
- -38.3%
- Average 2-day reaction, last 8
- -3.1%
- Positive 20 days after report
- 1 of 3
Analysts
- Consensus price target
- $162.67
- Target vs current price
- +39.3%
- Analysts with a rating
- 4
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | +10.4% | -1.6% | -2.3% | -6.2% | — |
| May 12, 2026 | -135.7% | -3.9% | -7.2% | -11.3% | +0.5% |
| Feb 25, 2026 | +10.3% | -3.7% | +2.9% | +45.0% | +140.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.58 | -$0.65 | +10.4% | — |
| May 12, 2026 | -$1.32 | -$0.56 | -135.7% | — |
| Feb 25, 2026 | -$1.63 | -$1.81 | +10.3% | — |
| Dec 3, 2025 | -$1.63 | — | — | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -1.61% | — | — | Top 41% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 12
- 50-day average slope (20 days)
- -3.0%
- Distance from 50-day average
- +8.7%
- RSI (14)
- 59.2
- Relative volume
- 0.79×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 65.5%
- Current drawdown from 1-year high
- -10.0%
- Maximum drawdown, 3 years
- -24.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jul 2, 2026 | Sep 1, 2026 | -24.8% | 42 days | Not yet recovered |
| May 5, 2026 | Jun 8, 2026 | -21.3% | 23 days | 11 days (Jun 24, 2026) |
| Mar 26, 2026 | Apr 7, 2026 | -16.1% | 7 days | 3 days (Apr 10, 2026) |
| Feb 18, 2026 | Feb 25, 2026 | -15.8% | 5 days | 8 days (Mar 9, 2026) |
| Apr 15, 2026 | Apr 24, 2026 | -15.7% | 7 days | 1 days (Apr 27, 2026) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $4.88B
- Revenue (TTM)
- $0
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 |
| Operating income | -$17.3M | -$26.8M | -$72.3M |
| Net income | -$16.5M | -$26.5M | -$70.0M |
| EPS (diluted) | -$0.08 | -$0.14 | -$2.38 |
| Q4 2024 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.7M | -$20.1M | -$21.8M | -$27.2M | -$23.5M |
| EPS (diluted) | -$0.03 | — | -$0.76 | -$0.80 | -$0.58 |
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Operating cash flow | -$13.5M | -$23.7M | -$71.6M |
| Capital expenditure | $0 | $0 | -$24,000 |
| Free cash flow | -$13.5M | -$23.7M | -$71.6M |
| Dividends paid | $0 | $0 | $0 |
| Net share buybacks | $0 | $52.8M | $156,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $819.9M
- Total assets
- $825.7M
- Total liabilities
- $12.1M
- Total debt
- $428,000
- Net debt
- -$318.9M
- Shareholders’ equity
- $813.6M
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 4,106,974
- Days to cover
- 7.48
- Change vs previous report
- +2.0%
FINRA short interest, settlement date Sep 15, 2026.